VANCOUVER, BC / ACCESSWIRE / August 12, 2020 / Gaia Metals Corp. (the "Company") (TSXV:GMC)(OTCQB:RGDCF)(FSE:R9G) is pleased to announce that field crews have mobilized to the Freeman Creek Property (the "Property") to carry-out a Phase I surface exploration program that will lay the foundation for the subsequent Phase II drill program. The Property is located approximately 15 km northeast of Salmon, in the State of Idaho, USA, and is accessible via paved highway and a network of gravel roads and trails.

The Phase I surface program will include the following components:

Verification of historical drill collar, adit, and open-cut locations

Property-wide prospecting and rock sampling

Property-wide ground magnetic survey

Soil sample grid extending across the Gold Dyke Prospect

The Property hosts two major advanced targets; the Gold Dyke Prospect, with an historical drill intercept of 1.5 g/t Au and 12.1 g/t Ag over 44.2 m (RDH 8), and the Carmen Creek Mine Prospect, with an historical outcrop sample assay of 14.15 g/t Au, 63 g/t Ag, and 1.2% Cu. Both prospect areas have seen sporadic exploration since the early 1900s, which includes high-grade Au-Ag samples of various outcrop and open-cuts as well as the completion of several adits (see news release dated June 4th, 2020). In the 1980s, several exploratory reverse circulation drill holes were completed at the Gold Dyke Prospect with many encountering near surface zones of anomalous gold mineralization, highlighted by the intersections in drill holes RDH 8 (above) and RDH 10 (1.7 g/t Au and 17.1 g/t Ag over 21.3 m). Strong grades of Cu, Pb, and Zn have also been reported, although were inconsistently assayed for.

The objective of the Phase I program is to verify these historical (i.e. pre-GPS era) drill collar, adit, and open-cut locations and to expand upon the surface mineralization that has been documented as far back as 1904. The soil sampling and magnetic survey will further aide with geological interpretation and trends over the target areas. Collectively the dataset derived from the Phase I surface exploration will orient the Phase II drill program anticipated to occur this fall.

Further in this regard, with the surface program now underway, the Company is actively planning the Phase II drill program. The Property is entirely located on BLM lands, outside of US Forest Service Lands and other protective areas. Therefore, the permitting process is relatively straightforward and efficient in comparison to other land designations where the process may be significantly more onerous. For optionality, the Company is permitting a total of eighteen (18) drill pad locations in support of an initial 1,000 m drill program (5 or 6 holes). These pad locations may be further modified based on results of the surface program currently underway.

The Gold Dyke Prospect, as the most advanced target on the Property, will be the focus of the initial drill program, which is anticipated to include twinning of the best historical drill intersections (core vs cuttings from historical drill holes RDH 8 and RDH 10), as well as drill testing of high-grade open-cut locations at depth. The primary objective of the drill program is to verify the historical drill results and gain additional understanding of the geology and orientation of the mineralized horizon(s), effectively setting the stage for a more expansive drill campaign.

Adrian Lamoureux, President, CEO, and Director of Gaia Metals Corp. comments, "Now that we have executed the Definitive Agreement for 100% ownership of the Freeman Creek Gold Property, we are immediately moving forward with an aggressive 2020 exploration campaign including drilling. Verification and expanding upon the historical results are the first steps toward unlocking the potential of this asset for our shareholders. With gold achieving historic highs, our timing couldn't be better".

NI 43-101 Disclosure

Darren L. Smith, M.Sc., P. Geo., Vice President of Exploration for the Company and Qualified Person as defined by National Instrument 43-101, supervised the preparation of the technical information in this news release.

About Gaia Metals Corp.

Gaia Metals Corp. is a mineral exploration company focused on the acquisition and development of mineral projects containing base and precious metals, including platinum group elements, and lithium.

The Company's flagship asset is the Freeman Creek Gold Property, located in Idaho, USA. The property hosts two major advanced targets; the Gold Dyke Prospect, with an historical drill intercept of 1.5 g/t Au and 12.1 g/t Ag over 44.2 m (RDH 8), and the Carmen Creek Mine Prospect, with an historical outcrop sample assay of 14.15 g/t Au, 63 g/t Ag, and 1.2% Cu.

Additional assets include the wholly owned Corvette Property, and the FCI Property (held under Option from O3 Mining Inc.) located in the James Bay Region of Quebec. The properties are contiguous and host significant gold-silver-copper-PGE-lithium potential highlighted by the Golden Gap Prospect with grab samples of 3.1 to 108.9 g/t Au from outcrop and 10.5 g/t Au over 7 m in drill hole, the Elsass and Lorraine prospects with 8.15% Cu, 1.33 g/t Au, and 171 g/t Ag in outcrop, and the CV1 Pegmatite Prospect with 2.28% Li2O over 6 m in channel.

In addition, the Company holds the Pontax Lithium-Gold Property, QC; the Golden Silica Property, BC; and the Hidden Lake Lithium Property, NWT, where the Company maintains a 40% interest, as well as several other assets in Canada.

For further information, please contact Adrian Lamoureux, President & CEO at Tel: 778-945-2950, E-mail: adrian@gaiametalscorp.com or visit www.gaiametalscorp.com.

On Behalf of the Board of Directors,
"ADRIAN LAMOUREUX"
Adrian Lamoureux, President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements:

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

SOURCE: Gaia Metals Corp.

ReleaseID: 601205

WEST PALM BEACH, FL / ACCESSWIRE / August 12, 2020 / Digital Resource is proud to be the 747th fastest-growing private company in America, as ranked by Inc. Magazine’s 2020 Inc. 5000. Only one in eight companies make the list three times.

With a 637.4% three-year growth rate between 2017 and 2019, the full-service Internet marketing agency is among an elite group of companies to make the list. In 2018, Digital Resource was ranked #262 on the annual list with a 1,855% three-year growth rate. In 2019, they appeared at #334 with a 1,400% growth rate.

Founder and President Shay Berman, age 28, says, “We are honored to have made this prestigious list for the third year in a row. It is a true testament to our team's ability to ignore the noise and stay obsessed with finding a better way. Numbers like this Inc. placement follow, they do not lead, and each and every team member here is a part of that leadership.”

He continues, “While we are extremely honored to have made the list based on our 2017-2019 numbers, we as a team are just grateful to be working and building our great clients back to the heights they all deserve to be at. To my team and fellow business owners – together, through hard work, empathy and understanding, we can beat this economic downfall caused by the pandemic."

To learn more about Digital Resource, please visit www.yourdigitalresource.com.

About Digital Resource: 

Founded in 2014, Digital Resource is a full-service Internet marketing agency based in West Palm Beach, Florida. The company’s winning solutions and experience deliver great results for businesses in all verticals across several key areas, including but not limited to search engine optimization, social media marketing and lead generation. Digital Resource pursues relationships based on transparency, persistence, mutual trust and integrity with its employees, clients and business partners. 

For more information, please direct all inquiries to Emily Creighton at 561-429-2585 or email press@yourdigitalresource.com.

Related Images

Related Links

Digital Resource Inc. 5000 2020 Celebration Video

Digital Resource Facebook

SOURCE: Digital Resource

ReleaseID: 601316

Increases Ability for U.S. Investors to Trade its Stock

YAVNE, ISRAEL / ACCESSWIRE / August 12, 2020 / A2Z Smart Technologies, Inc. (TSXV:AZ)(OTCQB:AAZZF)(FSE:A23) ("A2Z" or the "Company"), an innovative technology company specializing in state-of-the-art automation and electronics technology, is pleased to announce that the Company's stock has become DTC eligible, which enables the Company's securities to be deposited through DTC, the Depository Trust Company.

DTC is the largest securities depository in the world and holds over thirty-five trillion dollars worth of securities on deposit. DTC accepts deposits of securities from its participants only, who are usually clearing firms, and provides safekeeping through electronic record-keeping of securities balances. AAZZF will now be tradeable at U.S. online brokers, such as TD Ameritrade, E*Trade, Charles Schwab and Fidelity.

"Becoming DTC eligible coupled with our recent upgrade to OTCQB demonstrated our desire to become more attractive to U.S. investors", stated, Joseph Bentsur, A2Z's CEO. "While we continue our focus on sales growth, we are also committed to improving our capital markets strategy and we believe these recent moves will help us reach new potential investors."

About A2Z Smart Technologies, Inc.

A2Z Smart Technologies, Inc. is an innovative technology company based out of Israel, specializing in military technology and expanding into the civilian markets. A2Z has been operating for over 30 years and has a client base with 75 recurring clients, including the Israel Defense Forces, Security Forces, and Ministry of Defense among others. A2Z plans to leverage their cash flow-generating core-business to expand into the civilian robotics and automobile markets.

According to Zion Market Research, the Military Robotics space is expected to reach $53.93B by 2027 for a projected CAGR of 13.5%.(Summary of Report)

For additional information, please visit: https://a2zas.com
Twitter: @A@Z_Advanced

On Behalf of the Board,
Bentsur Joseph, CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to inherent risks and uncertainties. All statements within this news release, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those described in forward-looking statements. Factors that could cause actual results to differ materially from those described in forward-looking statements include fluctuations in market prices, including metal prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under applicable laws.

Corporate Contact:

Gadi Levin
+972-8-932-4333
gadi@a2zas.com  

Investors:

ClearThink
nyc@clearthink.capital

SOURCE: A2Z Technologies Canada Corp.

ReleaseID: 601222

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt") for an additional year.

To date, Helix and Moffitt have developed a new pancreatic adenocarcinoma mouse model suitable for testing the Company's lead clinical compound L-DOS47 alone or in combination with immunotherapies. Preliminary data includes how L-DOS47 may work with immunotherapy were shown in American Association for Cancer Research ("AACR") Annual Meeting 2019. In addition, in September 2019, at the World Molecular Imaging Conference, the Company and Moffitt jointly presented a poster presentation on the pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer ("CEST") and 31P-magnetic resonance spectroscopy ("31P-MRS"). The imaging technique is currently being used in the Company's U.S. clinical study in advanced stage pancreatic patients.

In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.

"I look forward to expanding the use of L-DOS47 in combination with immunotherapy for future clinical application", said Dr. Heman Chao, Helix's Chief Executive Officer.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor ("CAR") based cell therapies. Helix is currently listed on the TSX under the symbol "HBP".

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

Investor Relations

Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel. +1 (905) 841-2300
Email: ir@helixbiopharma.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Tel. + 1 (917) 385-2160
Email: helix@alphabronze.net

Cautionary Statements

This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to Helix's future business, operations, research and development, including Helix's activities relating to its drug development program, the anticipated timelines for the commencement or completion of certain activities, including enrolment of patients, the expansion of the DOS47 platform into other compounds and indications and other information in future periods. Forward-looking statements, which may be identified by words including, without limitation, "may", "improve", "planned", "possible", "postulated", "enhances", "potential", "development", "unique", "expects", "plans", "will", "intends", "pending", "objective", "exploring", "projected", and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation: (i) Helix's ability to operate as a going concern being dependent mainly on securing sufficient additional financing in order to fund its ongoing research and development and other operating activities; (ii) the generally inherent uncertainty involved in scientific research and drug development and those specific to Helix's pre-clinical and clinical development programs (DOS47, L-DOS47, V-DOS47 and CAR-T); (iiidifficulties in predicting accurate timelines for the commencement or completion of certain activities including those in support of ongoing clinical trials; (iv) positive preliminary results from early-stage clinical trials may not be indicative of the final results from the trial or be indicative of favorable outcomes in later-stage clinical trials; (v) delays or inability to complete clinical trials successfully and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (vi) clinical data may not demonstrate adequate efficacy and safety to result in regulatory approval to market any of Helix's product candidates in any jurisdiction; (vii) economic and market conditions may become worse and market shifts may require a change in strategic focus; and (viii) those risks and uncertainties affecting Helix as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors and assumptions are applied in making the forward-looking statements, including, without limitation, that sufficient financing will be obtained in a timely manner to allow Helix to continue operations and implement its clinical trials in the manner and on the timelines anticipated and that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.

SOURCE: Helix BioPharma Corp.

ReleaseID: 601224

JACKSON CENTER, PA / ACCESSWIRE / August 12, 2020 / Halberd Corp. (OTC PINK:HALB) today announced the addition of Edson Brito to the Scientific Advisory Board. Mr. Brito is CEO and Chief Business Development Officer of Cellybri Advanced Therapies in Brazil.

Mr. Brito graduated with a Chemistry degree from Faculdade São Bernardo and went on to study Pharmacology and Biochemistry at the Universidade Bandeirante de São Paulo, Brazil. He is a registered member of the Conselho Regional de Farmacia de São Paulo. Mr. Brito obtained a Master's degree in International Business Management and Marketing from the Instituto Paulista de Ensino e Pesquisa (IPEP) in São Paulo.

Mr. Brito has held various positions in sales and business development for a number of prominent pharma and biochemical companies in Brazil, and currently holds the position of Chief Business Development Officer and CEO of Cellybri Advanced Therapies in Brazil. Prior to his current position, Mr. Brito was Executive Consultant for Central and South America for the Korea Health Industry Development Institute – KHIDI of Seoul, South Korea. Prior to that, he held the position of Director of Business Development for Auramedi Farmaceutica, in Brazil.

William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "Mr. Britio brings a wealth of experience in Sales, Marketing and Business Development to Halberd Corporation, especially in the South American region. We hope his knowledge and skills will help us to quickly bring Covid-19 treatments to International Markets after receiving regulatory approvals."

Hartman continued, "Now that we have temporarily resolved issues regarding funding and team building, our current focus is on working with a shortened list of potential university partners to complete our R&D program to develop specific antibodies in select moieties and the optimum associated extraction process. We are making significant progress and should be able to release a status report shortly."

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133

Twitter:@HalberdC

About Halberd Corporation.
HalberdCorporation. (OTC PINK:HALB), is a publicly-traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Title

Application No.

Filing Date

Priority

Status

Method for Treating and Curing Covid-19 Infection

US 62/989981

03/16/2020

n/a

Provisional application Pending

Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients

US 63/007207

04/08/2020

n/a

Provisional application Pending

Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus

US 63/013104

4/21/2020

n/a

Provisional application Pending

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

ReleaseID: 601274

Eight of 23 samples returned over 41 gold grains with pristine grains accounting for 78% to 99%.
One sample returned 457 gold grains per 10kg fraction with 95% of the grains being pristine.

KINGSTON, ON / ACCESSWIRE / August 12, 2020 / Delta Resources Limited ("Delta" or "The Company") (TSXV:DLTA) (OTC PINK:GOLHF)(Frankfurt:6G01) is pleased to announce results from a till sampling orientation survey at the Delta-1 Property, 50 kilometres west of Thunder Bay, Ontario.

Gold grains were recovered from every till sample of the survey with eight samples returning between 41 and 457 gold grains (on a normalized 10kg fraction-size sample). With pristine grains accounting for 78% to 99% of the total gold grains. The pristine character of the gold grains indicates that there has been very little transport and hence these samples are interpreted to be proximal to a bedrock source for the gold.

André Tessier, President and CEO commented as follows:

"These are exceptional till results considering the limited number of samples collected, suggesting a very proximal and rich bedrock source. Even more interesting, the glacial trend from this survey coupled with our 2019 drill campaign (approximately 1000 metres in 6 holes) point to the same source for gold mineralization. Delta will be returning to the Delta-1 property in September to follow up and to initiate a property-scale till survey."

The survey was carried-out to determine the effectiveness of till sampling to indicate bedrock sources of gold mineralization at the Delta-1 Project. A total of only 23 till samples were collected in the eastern part of the property to cover an area surrounding the Kasper, Matawin, and Eureka gold occurrences.

Till sample "G" was instrumental in determining the effectiveness of the method as it was collected 35 metres down-ice from the Kasper gold occurrence and was found to contain 209 gold grains /10kg with 99% of the grains being pristine.

Sample A-10, for which the bedrock source is not known, returned 457 gold grains /10kg with 95% of the grains being pristine (see attached photo). Sample A-10, is located at the apex of a dispersion glacial trail (illustrated on the attached map) that points to a 700m long target area along a fault zone trending 080º azimuth located approximately 200m northwest of Delta's 2019 drill program which intersected up to 0.73 g/t gold over 22.0m in a broad zone of altered rocks grading 0.20 g/t gold over 137m (see Delta press release February 26, 2020). .

The complete table of results is as follows (see also the attached map):

Sample

Total Grains Recovered

Grain Morphology

% Pristine
Grains

Grains / 10kg
fraction < 1mm

Pristine

Modified

Reshaped

Till-A

18

13

3

2

72%

11.54

Till-B

6

4

2

0

67%

5.65

Till-C

10

3

5

2

30%

5.96

Till-D

4

1

3

0

25%

3.95

Till-E

8

5

3

0

63%

4.01

Till-F

19

11

5

3

58%

9.32

Till-G

223

221

2

0

99%

209.30

Till-H

4

2

1

1

50%

3.48

A1

6

2

3

1

33%

4.74

A2

44

37

7

0

84%

36.11

A3

40

36

4

0

90%

23.80

A4

73

64

8

1

88%

45.72

A5

43

36

6

1

84%

26.61

A6

46

45

1

0

98%

41.08

A7

11

9

1

1

82%

7.50

A8

38

33

4

1

87%

32.36

A9

116

100

15

1

86%

76.67

A10

418

397

21

0

95%

457.02

A11

12

12

0

0

100%

13.59

A12

7

5

2

0

71%

8.09

A13

58

45

10

3

78%

50.26

A14

107

105

1

1

98%

97.12

A15

115

98

16

1

85%

116.88

Geology map of the eastern part of the Delta-1 property showing the dispersion trail of high gold grain counts leading to a fault zone that is subsidiary to the Shebandowan Shear Zone..

SEM backscatter image Photo of gold grains from sample A-10 showing the pristine morphology of the grains.

The Delta-1 property is located in the Shebandowan Greenstone Belt and covers a 17km strike extent of the Shebandowan Structural Zone which also hosts the low-grade – high-tonnage Moss Lake gold deposit (Wesdome; WDO:TSX), 50 km to the west.

Sampling and Analytical Protocol

Till Sample Sites were selected based on availability of material and ease of access. Sample acquisition was facilitated by Excavator acquiring the most effective till horizon at or near bedrock interface (down-ice basal lodgement horizon of the oldest till deposit). Sample size varied between 11.6 and 22.5 kg. Samples were collected in new plastic pails, sealed, and shipped for analysis.

Till samples were analyzed by IOS Services Geoscientifiques of Chicoutimi, Quebec using the fully automated scanning electron microscope counting protocol Advanced Recovery Technology for Gold (ARTGold), an exclusive technology for the recovery of gold grains in till. ARTPhot procedure includes sieving (<1mm), concentration with fluidized bed, manual sorting for gold grain >50 microns, automated optical sorting for 20-50 micron and SEM validation of the grains.

All gold grains were extracted from the till samples, confirmed with a chemical analysis of each grain, their sizes were measured and each grain was classified by image analysis as "pristine", "modified" or "reshaped" to estimate the distance the gold grains were transported from their original bedrock source with pristine grains being the closest from the bedrock source.

QA/QC of the gold grain analysis is performed on 10% of the samples by reanalyzing fluidized rejects of the samples.

Qualified Person

Andre C. Tessier, P.Eng and P.Geo. President and CEO of Delta Resources Limited is a Qualified Persons as defined by NI-43-101 and is responsible for the technical information presented in this press release. Mr. Tessier has reviewed the drill core and the analytical results described herein.

About Delta Resources Limited

Delta Resources Limited is a Canadian mineral exploration company focused on growing shareholder value through the acquisition of high-potential gold and base-metal projects in Canada, exploring these projects with state-of-the-art methods, and potentially developing these projects into mines.

Delta is currently exploring its Eureka Gold Discovery in the Thunder Bay area (Delta-1) and its Delta-2 Gold-Polymetallic Property in the Chibougamau Mining District of Quebec.

Delta also owns a 100% interest in the Bellechasse-Timmins gold deposit in southeastern Quebec. On July 3rd, 2020, Delta announced the sale of the Bellechasse-Timmins project.

The Company continues to focus on building upon its strong portfolio of mineral exploration properties with a high potential for economic discoveries in Canada.

ON BEHALF OF THE BOARD OF DELTA RESOURCES LIMITED.

Andre C. Tessier
President, CEO and Director
www.deltaresources.ca

We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has not approved nor disapproved of the information contained herein.

For Further Information:

Delta Resources Limited
Frank Candido, Chairman, VP Corporate Communications
Tel : 514-969-5530
fcandido@deltaresources.ca

or

Andre Tessier, CEO and President
Tel: 613-328-1581
atessier@deltaresources.ca

Cautionary Note Regarding Forward Looking Information

Some statements contained in this news release are "forward looking information" within the meaning of Canadian securities laws. Forward looking information includes, but is not limited to, statements regarding: the samples may be proximal to a rich bedrock source for the gold; the possibility of the same source for gold mineralization; and the initiation of a property-scale till survey in September. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any particular event.

SOURCE: Delta Resources Limited

ReleaseID: 601275

TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business.

During the quarter, Edesa received Canadian regulatory approval to begin a Phase 2/Phase 3 clinical study of its biologic drug candidate, EB05, as a potential treatment for hospitalized COVID-19 patients. Based on previous clinical data and the drug's mechanism of action, the company believes that EB05 could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome (ARDS) – the leading cause of death in COVID-19 patients. In July, Edesa filed an investigational new drug (IND) application with the Food and Drug Administration to expand the company's planned clinical study to U.S. hospitals. Edesa also reported that protocol amendments to facilitate enrollment for its ongoing Phase 2b clinical study in allergic contact dermatitis have been implemented at the majority of the company's investigational centers.

"During the quarter, we continued the dosing of subjects in our dermatitis study, while simultaneously preparing for the launch of a Phase 2/3 study of our first biologic candidate – a novel monoclonal antibody targeting TLR4," said Dr. Par Nijhawan, Chief Executive Officer of Edesa. "The lack of effective therapies for ARDS has been made even more devastating by the COVID-19 pandemic, which can cause severe acute respiratory failure in up to 40% of hospitalized COVID-19 patients and up to 85% of patients admitted to the ICU." Dr. Nijhawan said that, subject to funding and IND approval, the company is presently on track to be ready to initiate patient enrollment ahead of the anticipated resurgence of SARS-CoV-2 infections this fall/winter.

Edesa's Chief Financial Officer Kathi Niffenegger reported that expenditures during the quarter reflected increased activities and preparations related to the planned COVID-19 study as well as trial expenses for the company's ongoing dermatitis study. She also noted that subsequent to the quarter end the company has received cash proceeds of approximately $2.42 million as a result of exercises of common share purchase warrants.

"We have built flexibility into our business planning processes, and have prioritized working capital for our clinical projects based on their feasibility amid the pandemic, the nearness of their inflection points and their ability to address significant unmet medical needs," said Ms. Niffenegger.

Financial Results for the Three Months Ended June 30, 2020*

Total revenues for the three months ended June 30, 2020 were $0.11 million, reflecting sale of product inventory obtained in the reverse acquisition completed in June 2019. There were no significant revenues for the three months ended June 30, 2019.

Total operating expenses increased by $0.56 million to $1.88 million for the three months ended June 30, 2020 compared to $1.32 million for the same period last year:

Cost of sales and services was less than $0.01 million for the three months ended June 30, 2020, reflecting the sales of product inventory obtained in the reverse acquisition. There were no product sales in the same period last year.

Research and development expenses increased by $0.64 million to $1.14 million for the three months ended June 30, 2020 compared to $0.50 million for the same period last year. The increase was primarily due to increased external research expenses related to the clinical study of the company's EB01 drug candidate, and increased activities and preparations related to the planned Phase 2/Phase 3 clinical study of EB05 as a potential treatment for hospitalized COVID-19 patients.

General and administrative expenses decreased by $0.09 million to $0.73 million for the three months ended June 30, 2020 compared to $0.82 million for the same period last year primarily due to a decrease in legal fees, which was partially offset by increased salary and related personnel expenses and higher public company expenses.

For the three months ended June 30, 2020, Edesa reported a net loss of $1.77 million, or $0.20 per basic share, compared to a net loss of $1.29 million, or $0.30 per basic share, for the three months ended June 30, 2019.

Financial Results for the Nine Months Ended June 30, 2020*

Total revenues for the nine months ended June 30, 2020 were $0.33 million, reflecting sale of product inventory obtained in the reverse acquisition completed in June 2019. There were no significant revenues for the nine months ended June 30, 2019.

Total operating expenses increased by $2.45 million to $4.72 million for the nine months ended June 30, 2020 compared to $2.27 million for the same period last year:

Cost of sales and services was $0.02 million for the nine months ended June 30, 2020, reflecting the sales of product inventory obtained in the reverse acquisition. There were no product sales in the same period last year.

Research and development expenses increased by $1.30 million to $2.17 million for the nine months ended June 30, 2020 compared to $0.87 million for the same period last year. The increase was primarily due to increased external research expenses related to the clinical study of the company's EB01 drug candidate, and increased activities and preparations related to the planned Phase 2/Phase 3 clinical study of EB05 as a potential treatment for hospitalized COVID-19 patients, as well as increased salary and related personnel expenses.

General and administrative expenses increased by $1.13 million to $2.53 million for the nine months ended June 30, 2020 compared to $1.40 million for the same period last year. The increase was primarily due to increased salary and related personnel expenses, increased legal and professional fees, and higher public company expenses.

For the nine months ended June 30, 2020, Edesa reported a net loss of $4.35 million, or $0.52 per basic share, compared to a net loss of $2.19 million, or $0.61 per basic share, for the nine months ended June 30, 2019.

* Financial results for any periods ended prior to June 7, 2019 reflect the financials of the company's subsidiary Edesa Biotech Research, Inc. on a standalone basis.

Working Capital

At June 30, 2020, Edesa had working capital of $5.24 million. Cash and cash equivalents totaled $5.64 million. From July 8 to August 10, 2020, the exercise of common share purchase warrants resulted in net cash proceeds to the company of approximately $2.42 million.

Calendar

Edesa management will be remotely joining the H.C. Wainwright Global Investment Conference on September 14-16, 2020 and the LD Micro 500 conference being held September 1-4, 2020. Attendees interested in meetings with management can schedule video one-on-one meetings through the conferences or by contacting Edesa at investors@edesabiotech.com.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. The company is developing late-stage monoclonal antibodies that block certain immune signaling proteins, known as TLR4 and CXCL10. These molecules are associated with a broad range of diseases, including the inflammation associated infectious diseases. Due to the global health emergency, Edesa has prioritized the development of EB05 as a potential treatment for hospitalized COVID-19 patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: the company's belief that EB05 could regulate the overactive immune response associated with ARDS and the company's plans regarding its Phase 2/3 study, including its belief that, subject to funding and IND approval, the company could be ready to initiate patient enrollment ahead of the anticipated resurgence of SARS-CoV-2 infections this fall/winter. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contacts

Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

Condensed Interim Consolidated Statements of Operations
(Unaudited)

 
Three Months Ended
 
 
Nine Months Ended
 

 
June 30, 2020
 
 
June 30, 2019
 
 
June 30, 2020
 
 
June 30, 2019
 

Total Revenues

 
$ 
109,985
 
 
$ 
500
 
 
$ 
328,301
 
 
$ 
500
 

Expenses:

Cost of sales and services

 
 
1,472
 
 
 
–
 
 
 
15,287
 
 
 
–
 

Research and development

 
 
1,143,868
 
 
 
502,927
 
 
 
2,174,680
 
 
 
872,020
 

General and administrative

 
 
733,079
 
 
 
817,927
 
 
 
2,528,702
 
 
 
1,395,353
 

 
 
1,878,419
 
 
 
1,320,854
 
 
 
4,718,669
 
 
 
2,267,373
 

Loss from Operations

 
 
(1,768,434)
 
 
 
(1,320,354
)
 
 
(4,390,368)
 
 
 
(2,266,873
)

Other Income

 
 
2,671
 
 
 
26,347
 
 
 
41,436
 
 
 
79,187
 

Income Tax Expense

 
 
–
 
 
 
–
 
 
 
800
 
 
 
–
 

Net Loss

 
 
(1,765,763)
 
 
 
(1,294,007
)
 
 
(4,349,732)
 
 
 
(2,187,686
)

Exchange differences on translation

 
 
68,972
 
 
 
27,443
 
 
 
47,178
 
 
 
118,456
 

Net Loss and Comprehensive Loss

 
$ 
(1,696,791)
 
 
$ 
(1,266,564
)
 
$ 
(4,302,554)
 
 
$ 
(2,069,230
)

Weighted average number of common shares outstanding

 
 
8,859,520
 
 
 
4,317,759
 
 
 
8,364,866
 
 
 
3,599,188
 

Loss per share – basic and diluted

 
$ 
(0.20)
 
 
$ 
(0.30
)
 
$ 
(0.52)
 
 
$ 
(0.61
)

Condensed Interim Consolidated Balance Sheets
(Unaudited)

 
June 30,
 
 
September 30,
 

 
2020
 
 
2019
 

Assets:

Cash and cash equivalents

 
$ 
5,640,695
 
 
$ 
5,030,583
 

Other current assets

 
 
580,112
 
 
 
614,123
 

Intangible asset

 
 
2,508,829
 
 
 
–
 

Operating lease right-of-use assets

 
 
172,776
 
 
 
–
 

Property and equipment, net

 
 
20,342
 
 
 
73,058
 

Total Assets

 
$ 
8,922,754
 
 
$ 
5,717,764
 

Liabilities, shareholders' equity and temporary equity:

Current liabilities

 
$ 
983,078
 
 
$ 
461,634
 

Noncurrent liabilities

 
 
139,487
 
 
 
–
 

Temporary equity

 
 
2,458,051
 
 
 
–
 

Shareholders' equity

 
 
5,342,138
 
 
 
5,256,130
 

Total liabilities, shareholders' equity and temporary equity

 
$ 
8,922,754
 
 
$ 
5,717,764
 

Condensed Interim Consolidated Statements of Cash Flows
(Unaudited)

 
Nine Months Ended
 

 
June 30, 2020
 
 
June 30, 2019
 

Cash Flows from Operating Activities:

Net loss

 
$ 
(4,349,732)
 
 
$ 
(2,187,686
)

Adjustments for non-cash items

 
 
540,945
 
 
 
36,639
 

Change in working capital items

 
 
495,384
 
 
 
(1,749,912
)

Net cash used in operating activities

 
 
(3,313,403)
 
 
 
(3,900,959
)

Net cash provided by investing activities

 
 
15,532
 
 
 
6,405,207
 

Net cash provided by financing activities

 
 
3,864,307
 
 
 
–
 

Effect of exchange rate changes on cash and cash equivalents

 
 
43,676
 
 
 
128,618
 

Net change in cash and cash equivalents

 
 
610,112
 
 
 
2,632,866
 

Cash and cash equivalents, beginning of period

 
 
5,030,583
 
 
 
3,730,230
 

Cash and cash equivalents, end of period

 
$ 
5,640,695
 
 
$ 
6,363,096
 

SOURCE: Edesa Biotech

ReleaseID: 601212

OTTAWA, ON / ACCESSWIRE / August 12, 2020 / This fall's federal budget will be critical in supporting Canada's economic and social recovery. Not only will it offer an opportunity for the federal government to consider what is required for the health and well-being of Canadians, but also what we need to do, as a country, to attract investment, diversify our economy and create more prosperity for all Canadians.

On the road to economic recovery and health care sustainability post-COVID-19, the innovative pharmaceutical industry can play an active role in helping Canadians emerge from the pandemic.

"Working together, we can achieve a stable, innovative life sciences environment that provides better health, access to new medicines, economic opportunities, and enhanced protection and preparedness in the wake of the global pandemic," said Innovative Medicines Canada President Pamela Fralick.

IMC has three recommendations, and suggests the government should:

Strike a balance between affordability and access to innovative medicines and vaccines. Balance can be achieved by suspending changes to the Patented Medicine Prices Review Board (PMPRB) and working together to ensure affordable treatments and vaccines are rapidly available to Canadians.

Provide additional funding and research incentives over the next 5 years to antimicrobial resistance (AMR) One-Health Network and work with the Canadian Antimicrobial Innovation Coalition (CAIC) to address the growing public health threat of AMR.

Work in cooperation with the provinces, territories, life sciences organizations and the pharmaceutical industry to develop a National Life Sciences Strategy (NLSS) for Canada and implement it over the next 10 years with appropriate funding.

These meaningful policy objectives are at risk given the PMPRB's new regime, which will undermine our industry's capacity to continue investing and to maintain current levels of clinical trial activity in our country. The PMPRB regulations will have particularly severe impacts on many new rare disease medicines, and will impact their availability in Canada, which will make a rare disease framework ineffective. They will also result in a reduction in the number of clinical trials in Canada, and reduced investment in the country's life sciences sector.

IMC's written submission for the pre-budget consultations in advance of the upcoming 2021 federal budget is available online .

About Innovative Medicines Canada

Learn more about how our member companies are contributing to the fight against COVID-19.

Innovative Medicines Canada is the national voice of Canada's innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members' commitment to being valued partners in the Canadian healthcare system.

For further information:

Sarah Dion-Marquis
Director, Media and Public Relations
Telephone: 613-769-6510
E-mail: sdmarquis@imc-mnc.ca

SOURCE: Innovative Medicines Canada

ReleaseID: 601280

Single CRV431 Administration Inhibited Hepatitis C Infection in Humanized Liver Mouse Model, with no Viral Rebound

EDISON, NJ / ACCESSWIRE / August 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that the peer-reviewed journal, PLOS ONE, has published a paper that further elucidates antiviral activities of CRV431, Hepion's lead drug candidate, which is currently in a Phase 2a clinical trial for NASH fibrosis.

The article reviews a study, conducted by Dr. Philippe Gallay's research group at The Scripps Research Institute, investigating the ability of CRV431 and NV556, two structurally different cyclophilin inhibitors, to inhibit hepatitis C virus ("HCV") replication in vivo. The paper, entitled, "Structurally Distinct Cyclosporin and Sanglifehrin Analogs CRV431 and NV556 Suppress Established HCV Infection in Humanized-Liver Mice" is co-authored by Dr. Daren Ure, Hepion's Chief Scientific Officer, and Dr. Robert Foster, Hepion's CEO.

Mice implanted with human hepatocytes were subsequently infected with HCV and simultaneously administered either 50 mg/kg CRV431, 50 mg/kg NV556 or vehicle control. Vehicle-treated mice demonstrated HCV replication reaching peak viremia at nine weeks post infection, whereas HCV infection was completely abolished in mice treated with CRV431 or NV556. When CRV431 and NV556 were administered to mice at three- and six-weeks post HCV infection, HCV replication was totally inhibited at nine- and 12-weeks, respectively. In addition, no viral rebound was observed five months following a single CRV431 or NV556 administration, indicating the possibility of the complete suppression of an established viral infection.

"We have conducted a number of in vitro and in vivo studies that have demonstrated CRV431's antiviral activity toward hepatitis B, HCV and HIV-11," said Dr. Ure. "This study adds to the consistent body of data indicating that CRV431 exhibits antiviral activity across multiple types of viral infection."

Dr. Philippe Gallay, Professor, Department of Immunology and Microbial Science at the Scripps Research Institute, commented, "A primary focus of our research has been on the interaction of cyclophilins and various viruses, and we are impressed with CRV431's continued demonstration of antiviral activity. The many isoforms of cyclophilins and their diverse actions are the reasons why they are uniquely versatile drug targets in multiple indications, including viral infection, inflammation, fibrosis and cancer. This study suggests that cyclophilin inhibitors provide additive-to-synergistic anti-HCV activity when combined with direct-acting antivirals, and moreover, may help overcome certain viral variants' resistance to these treatments."

Dr. Foster added, "While we continue to focus on our Phase 2a trial of CRV431 for the treatment of NASH, we are excited by these results, which provide additional support of CRV431's antiviral activity across several types of viral infection. These new data, in addition to a recent in vitro study showing that particular concentrations of CRV431 attenuate SARS-CoV-2 by up to 90% in certain cell types, warrant further investigation of CRV431's utility in treating COVID-19."

The article may be accessed at: https://doi.org/10.1371/journal.pone.0237236

1 Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R (2015) The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. PLOS One. doi. 10.1371/journal.pone.0134707.

About Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on Hepion Pharmaceuticals' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

SOURCE: Hepion Pharmaceuticals, Inc.

ReleaseID: 601278

The Shoppes at Montage Mountain

SCRANTON, PA / ACCESSWIRE / August 12, 2020 / U.S Properties Group (USPG) continues its successful leasing activity at The Shoppes at Montage Mountain shopping center in Moosic, Pennsylvania. Its latest signed lease, a 10,000 square foot Versona, is slated to open September 24th, 2020.

Versona, a fun apparel, jewelry, and accessories brand that centers on the unique approach to fashion, welcomes its inclusion at The Shoppes at Montage Mountain. The popular "priced right everyday fashion" store centers around the customer – "The heart of everything we do." Their clientele is of the unique club that take risks with their fashion, but not their budget. The collective group budgets their time with work, family, and social commitments. Versona capitalizes on these traits and offers a one-stop-shop to complete a look from head to toe. Their guest shoppers possess and express individual style that doesn't conform and stands out.

The Shoppes at Montage Mountain is performing very well in the Wilkes-Barre/Scranton area. With the current opening rate of stores affected by the pandemic at 95%, the planned re-opening of Harvest Seasonal Grill slated for mid-August will bring it to 98%. The center continues to supply the area with a great assortment of restaurant and entertainment venues, which are open and producing quality offerings under a safe and COVID-19 restricted environment.

Gord Wiebe, Director of USPG states: "Moosic, Pennsylvania continues its growth and The Shoppes at Montage Mountain is the premier place to shop. We at U.S. Properties Group are seeing continued trends to occupy and favor our outdoor open-air centers as their first choice of locations. We appreciate all of our tenants and the important role of businesses that will help fuel the local economy and attract guests to our centers. Versona is a quality addition that keeps the brick and mortar retail world alive and vibrant."

Tim Todaro, VP Leasing and Development for USPG notes: "The addition of this business adds that key factor of active retail – representing and supporting the local community – and keeps the lively retail offerings that make The Shoppes at Montage Mountain the place to shop, dine and entertain in the Moosic and surrounding areas."

About The Shoppes at Montage Mountain:

The Shoppes at Montage Mountain is Northeastern Pennsylvania's first and only Lifestyle Center and is conveniently located between Scranton and Wilkes-Barre. Amid inviting gathering spots, wide sidewalks, and convenient parking in close proximity to individual shops and eateries, they offer a unique range of premium shops and restaurants, such as Food & Fire BBQ and Taphouse, J. Crew Mercantile, Fine Wine & Good Spirits, Panera Bread, DSW Shoes and much more. The Shoppes at Montage Mountain features many premium tenants and is conveniently located off I-81, Exit 182, Montage Mountain Road. For more tenant information and deals visit – www.shoppesatmontage.com

U.S. Properties Group is growing and owns approximately four million square feet. Redeveloping shopping centers in 10 states and managing over 350 tenant relationships, USPG covers the Midwest and Southeast United States, which includes Alabama, Georgia, Illinois, Michigan, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Virginia. Founded to create value and realize the "Upcycling" of shopping center assets, USPG and their team of professionals utilize their skills in acquisitions, development, renovation, and management to enhance property values and restore the community marketplace­s with best of class tenants and services. For more information visit www.uspginc.com

CONTACT:
U.S. Properties Group
Erin Kosek, Property Management
U.S. Properties Group
1035 Shoppes Boulevard
Moosic, PA 18507
570-341-3271
ekosek@uspginc.com

For all leasing inquiries:

Tim Todaro
U.S. Properties Group
3665 Fishinger Blvd.
Hillard, OH 43026
Direct 614-472-2930
Cell 614-969-9523
ttodaro@uspginc.com
www.uspginc.com

SOURCE: U.S. Properties Group, Inc.

ReleaseID: 601338